论文部分内容阅读
目的:通过对Ⅰ期子宫内膜癌患者手术后服用孕激素治疗的随访研究,探讨孕激素辅助治疗对Ⅰ期子宫内膜癌患者预后的影响。方法:选取本院妇科2004年1月～2009年1月诊断为Ⅰ期子宫内膜癌手术病人84例,随机将病人分为孕激素治疗组42例和未用孕激素对照组42例,治疗组病人除与对照组相同治疗外每天口服甲羟孕酮250毫克,连续服用12个月。2组患者随访观察3年,进行回顾性分析。结果:孕激素治疗组与对照组3年内复发率分别为7.14%和16.6%,两者差异有统计学意义(P<0.05)。孕激素治疗组与对照组3年存活率分别为95.2%和88.3%两者差异有统计学意义(P<0.05)。结论:通过对Ⅰ期子宫内膜癌患者手术后服用孕激素治疗的随访观察,认为术后孕激素辅助治疗可以改善Ⅰ期子宫内膜癌患者的预后。
Objective: To investigate the effect of progestin adjuvant therapy on the prognosis of patients with stage Ⅰ endometrial cancer through follow-up study of patients with stage Ⅰ endometrial cancer after operation. Methods: Eighty-four patients with stage I endometrial cancer diagnosed as gynecological department from January 2004 to January 2009 were randomly divided into two groups: 42 cases in the progestin group and 42 cases in the non-progesterone group Group of patients in addition to the same treatment with the control group, oral medroxyprogesterone 250 mg daily for 12 months. Two groups of patients were followed up for 3 years and analyzed retrospectively. Results: The recurrence rates of progestin group and control group within 3 years were 7.14% and 16.6%, respectively, with statistical significance (P <0.05). The 3-year survival rates of progestin-treated group and control group were 95.2% and 88.3%, respectively, with significant difference (P <0.05). Conclusion: The follow-up observation of patients with stage Ⅰ endometrial cancer after taking estrogen and progesterone treatment shows that postoperative progestin adjuvant therapy can improve the prognosis of stage Ⅰ endometrial cancer patients.